CommentClinical update: adverse effects of antiretroviral therapy
References (20)
- et al.
Cardiovascular risk and body-fat abnormalities in HIV-infected adults
N Engl J Med
(2005) - et al.
Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week trial in antiretroviral-naive adults
Antivir Ther
(2006) - et al.
Metabolic outcomes of ACTG 5142
14th CROI
(2007) - et al.
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy
AIDS
(2006) - et al.
Effect of pioglitazone on HIV-1 related lipoatrophy
13th CROI
(2006) - et al.
Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy (HAL)
7th Int Workshop on Adverse Events and Lipodystrophy in HIV
(2005) - et al.
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men
AIDS
(2006) - et al.
A comparison of factors associated with prevalent diabetes mellitus among HIV-infected, antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey Cohort
J Acquir Immune Defic Syndr
(2007) Class of antiretroviral drugs and the risk of myocardial infarction
N Engl J Med
(2007)- et al.
Interruption of ART and risk of cardiovascular disease: findings from SMART
14th CROI
(2007)
Cited by (66)
Lipodystrophy related to HIV—The Brazilian Public Health approach
2022, Journal of Plastic, Reconstructive and Aesthetic SurgeryCitation Excerpt :Nevertheless, mortality is decreasing, and HIV is becoming a lifelong chronic disease.1 However, despite improved life expectancy and reduced transmission rate, antiretroviral therapy (ART) has a broad spectrum of adverse events and side effects, even with the newer generation of drugs2. Fatigue, nausea, vomiting, diarrhea, and sexual disorders are some non-specific symptoms, and cardiovascular and metabolic complications can occur.2
Muscle mass, strength, bone mineral density and vascular function in middle-aged people living with HIV vs. age-matched and older controls
2021, Brazilian Journal of Infectious DiseasesNanotechnology for virus treatment
2021, Nano TodayGluT4: A central player in hippocampal memory and brain insulin resistance
2020, Experimental NeurologyCitation Excerpt :This dual activity offers a potential human model in which to assess the specific impact of GluT4 blockade: patients treated with GluT4-impairing protease inhibitors (PI; indinavir, nelfinavir) vs. those treated with the newer atazanavir, which has a low affinity for GluT4 (Hruz et al., 2008). A common consequence of HIV infection is cognitive impairment including brain pathology, commonly referred to as HIV-associated neurocognitive disorder (HAND) (Clifford and Ances, 2013); the prevalence of HAND has not decreased concomitantly with e.g. decreased viral load (Calmy et al., 2007; Samaras et al., 2007; Carr, 2003; Lindl et al., 2010; Winston et al., 2010; Gannon et al., 2011) and is roughly 30–50% among HIV-infected persons (Heaton et al., 2010). Long-term PI use has been linked to HAND, with symptoms including hippocampal cognitive impairment and Aβ accumulation, resembling central insulin resistance (Green et al., 2005).
Current Progress in the Pharmacogenetics of Infectious Disease Therapy
2017, Genetics and Evolution of Infectious Diseases: Second EditionElevated adiponectin prevents HIV protease inhibitor toxicity and preserves cerebrovascular homeostasis in mice
2016, Biochimica et Biophysica Acta - Molecular Basis of Disease